David M. O'Malley, MD, The Ohio State University
Articles by David M. O'Malley, MD, The Ohio State University
David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.
David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.
The Future of Endometrial Cancer Treatment
ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Experts give insight on what they are looking forward to in the endometrial cancer space.
A Look at Surgical Innovations in EC
ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.
Novel Targets of Interest in EC
ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.
Insight on Ongoing Trials in EC
ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.
Incorporating Molecular Features into Choosing Adjuvant Therapy
ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.
Therapeutic Sequencing in Endometrial Cancer
ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.
Managing AEs With Pembrolizumab and Lenvatinib
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.
Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.
A Discussion on the Study 309/KEYNOTE-775 Data
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.
Results from Study 309/KEYNOTE-775
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.
Study 309/KEYNOTE-775 Trial Design
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.
Therapeutic Approaches in Endometrial Cancer
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.
Biomarker Testing and Multidisciplinary Approaches in EC
ByBradley J. Monk, MD, FACS, FACOG, University of Arizona,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.
Heterogeneity of Endometrial Cancer
ByBradley J. Monk, MD, FACOG, FACS, University of Arizona,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..
Future of Advanced Endometrial Cancer
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine 
Novel Targets for Advanced Endometrial Cancer
ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine
Study 309/KEYNOTE-775 Trial Design
Managing AEs With Pembrolizumab and Lenvatinib
A Discussion on the Study 309/KEYNOTE-775 Data
Therapeutic Approaches in Endometrial Cancer
Results from Study 309/KEYNOTE-775
Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer